Navigation Links
CareFusion Reports Second Quarter Results
Date:2/9/2010

nclude:

  • Introducing under limited release new minimally invasive interventional products to treat spinal compression fractures. With planned general availability in April, CareFusion will offer a complete line of products for both kyphoplasty and vertebroplasty procedures;
  • Signing a 10-year, sole-source agreement to upgrade Tenet Healthcare's entire network of 50 member hospitals with the Alaris® system infusion pumps;
  • FDA lifting an injunction on manufacture and sale of the CareFusion Alaris® SE pump;
  • The New England Journal of Medicine publishing a study showing the superiority of CareFusion ChloraPrep® compared to povidone-iodine for surgical skin preparation;
  • Announcing six new Pyxis® medication management products at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition; and
  • Launching the CareFusion Knowledge Portal, a Web-based application providing hospitals with on-demand information to improve efficiency and medication safety, while reducing costs.

Fiscal 2010 Outlook

CareFusion increased its revenue guidance range to a range of $3.95 billion to $4.05 billion, up from the previous guidance range of $3.85 billion to $4.0 billion. In addition, the company narrowed its previously provided adjusted diluted EPS outlook for fiscal 2010 to a range of $1.40 to $1.45, the upper end of its previously provided guidance range of $1.35 to $1.45. The guidance for fiscal 2010 is based on an assumed diluted weighted average outstanding share count of approximately 223 million.

Conference Call

CareFusion will host a conference call today at 2 p.m. PST to discuss e
'/>"/>

SOURCE CareFusion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... The PT ... other clinically relevant measures for physical therapy patients. The Registry is being developed by ... FOTO, Inc. stated "We are happy to be selected to contribute FOTO Outcomes measures ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations website, ... specific translation services within the medical and pharmaceutical industries. These are industries that ... work. , ITC Global Translations specializes in professional translation services for materials used ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
(Date:8/31/2015)... Metamora, Michigan (PRWEB) , ... August 31, 2015 ... ... launched pre and postnatal fitness classes. , Starting September 1st they ... are called "The Mom Bod" and "Healthy Body, Healthy Baby." , More information ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... The Sundance ... on Tuesday, September 1. , “Alive Inside” shadows a social worker who advocates ... MEMORY?.” , “It’s a documentary about bringing music to residents in health care centers ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... Insomnia is common in Spain, and affects one person in ... out by the Vall d,Hebron University Hospital in Barcelona and ... 40% of survey respondents aged over 65 report interrupted sleep ... "Good sleep hygiene is necessary in order to avoid primary ...
... 2010 was the discovery of a "golden ratio" in ... forth the new suggestion that matter on the quantum ... opposed to chaos. Stories on the health sciences ... in 2010. The most popular topics varied from neurological ...
... , WEDNESDAY, March 23 (HealthDay News) -- Reducing ... 80 hours a week has not had a negative effect ... training of new doctors, a new study contends. The ... from the United States and United Kingdom, challenge concerns expressed ...
... every year there are reports of a young, apparently healthy athlete ... of Wes Leonard, a junior at Fennville High School, who died ... have parents and coaches wondering if enough is being done to ... to develop a better screening program to help prevent sudden cardiac ...
... Anderson Cancer Center has been awarded a grant to study ... neck cancer radiation treatment, can be prevented when acupuncture is ... grant awarded by the National Cancer Institute (NCI) for the ... peer scientists evaluating grant proposals for NCI. Lorenzo Cohen, ...
... -- The death rate of patients with chronic myeloid leukemia ... treatment was similar to the death rate in the general ... on 832 patients who were taking Gleevec (imatinib) for up ... the follow-up period. That death rate of 4.8 percent, however, ...
Cached Medicine News:Health News:1 in every 5 Spaniards suffers from insomnia 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 3Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 4Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 5Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: